NCT03698994
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAF, RAS, GNA, MAPK, NF1/2
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases:
Additional Notes: Patient must have enrolled on the Pediatric MATCH Screening Trial (NCT03155620)
Exclusions: Patients over the age of 21; Patients who have received prior exposure to BVD-523FB (ulixertinib) or other ERK inhibitors
https://ClinicalTrials.gov/show/NCT03698994